Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
BBIO Stock Chart & Stats
$68.05
-$0.10(-0.35%)
At close: 4:00 PM EST
$68.05
-$0.10(-0.35%)
Day’s Range― - ―
52-Week Range$28.33 - $81.33
Previous CloseN/A
Volume379.31K
Average Volume (3M)2.64M
Market Cap
$13.11B
Enterprise Value$14.33B
Total Cash (Recent Filing)$645.94M
Total Debt (Recent Filing)$1.86B
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Feb 19, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding192,708,820
10 Day Avg. Volume2,752,600
30 Day Avg. Volume2,642,520
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)-3.48
Price to Sales (P/S)23.01
P/FCF Ratio-9.79
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue40.51
Enterprise Value/Gross Profit42.29
Enterprise Value/Ebitda-21.16
Forecast
1Y Price Target
$98.50Price Target Upside44.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial MomentumAnalyst highlights strong launch traction for Attruby, with the drug taking a meaningful share of new treatment starts while being priced below the incumbent and delivering differentiated clinical stabilization, supporting continued revenue growth.
Diversified Late‑stage PipelineAnalyst notes a diversified late‑stage pipeline, including a pivotal achondroplasia program and other near‑term clinical catalysts, which should provide multiple future revenue streams and offset isolated commercial risks.
Path To ProfitabilityAnalyst projects a path to positive net income and free cash flow as commercial performance strengthens and operating expenses remain relatively modest, indicating potential for sustainable profitability.
Bears Say
Generic Competition And Combo TherapiesAnalyst cautions that earlier‑than‑expected generic tafamidis entry or competitive combo therapies could limit Attruby's long‑term market share and constrain upside in the share price.
Market Reaction And VolatilityAnalyst notes that the verbal withdrawal of a European patent triggered a sharp share decline and increased market volatility, which may keep investor sentiment subdued until litigation or patent positions are clarified.
Patent And Exclusivity RiskAnalyst warns that the European patent revocation reduces anticipated exclusivity for tafamidis and raises the possibility of earlier generic entry that could pressure future revenue.
BridgeBio Pharma News
BBIO FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was $28.32 and its highest was $81.33 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
BridgeBio Pharma Inc’s market cap is $13.11B.
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is Feb 19, 2026 which is in 10 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
BridgeBio Pharma Inc released its earnings results on Oct 29, 2025. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.894 by -$0.056.
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate is -0.72.
How many shares outstanding does BridgeBio Pharma Inc have?
BridgeBio Pharma Inc has 192,708,820 shares outstanding.
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
BridgeBio Pharma Inc reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.894. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Currently, no hedge funds are holding shares in BBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$98.50 (44.75% Upside)
$98.50 (44.75% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
50.12%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
BBIO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased positive developments with successful Phase III trial results and strong financial performance. However, challenges such as market access competition and increased operating expenses were noted.View all BBIO earnings summariesBBIO Stock 12 Month Forecast
Average Price Target
$98.50
▲(44.75% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Ionis Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Moderna
―
Ownership Overview
20.81% Insiders
21.80% Mutual Funds
0.07% Other Institutional Investors
42.66% Public Companies and Individual Investors